Palo Alto Investors LP - 30 Sep 2024 SCHEDULE 13G/A Report for Revance Therapeutics, Inc. Common Stock (RVNC)

Filing Manager
Palo Alto Investors LP
Reporting Manager
Patrick Lee, MD
Security
Revance Therapeutics, Inc. Common Stock
Symbol
RVNC
Shares outstanding
104,661,494 shares
Disclosed Ownership
1,611,787 shares
Ownership
1.5%
Form type
SCHEDULE 13G/A
Filing time
13 Feb 2025, 16:02:42 UTC
Date of event
30 Sep 2024
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Palo Alto Investors LP disclosed 1.5% ownership in Revance Therapeutics, Inc. Common Stock (RVNC) on 30 Sep 2024."

Quick Takeaways

  • Palo Alto Investors LP filed SCHEDULE 13G/A for Revance Therapeutics, Inc. Common Stock (RVNC).
  • Disclosed ownership: 1.5%.
  • Date of event: 30 Sep 2024.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 13 Feb 2025, 16:02.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (4)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Patrick Lee, MD 1.5% 1,611,787 0 1,611,787 Patrick Lee, MD Patrick Lee, MD
Anthony Joonkyoo Yun, MD 1.5% 1,611,787 0 1,611,787 Anthony Joonkyoo Yun, MD Anthony Joonkyoo Yun
Palo Alto Investors LP 1.5% 1,611,787 0 1,611,787 Angela Nguyen-Dinh Angela Nguyen-Dinh, Chief Compliance Officer
PAI LLC 1.5% 1,611,787 0 1,611,787 Patrick Lee, MD Patrick Lee, MD, Managing Member

Sponsored